Related Experiment Video
Updated: May 25, 2026
08:57
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
Published on: February 10, 2023
[Therapeutic responsiveness in chronic inflammatory demyelinating polyradiculoneuropathy]
1Department of Neurology, Nagoya University.
Rinsho Shinkeigaku = Clinical Neurology
|January 27, 2012
Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) pathogenesis involves immune systems and axonal dysfunction. TAG-1 gene variations impact IVIg treatment response in CIDP patients.
Area of Science:
- Neurology
- Immunology
- Genetics
Context:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune peripheral neuropathy with diverse clinical presentations.
- The precise pathogenesis of CIDP and factors influencing treatment response remain incompletely understood.
Purpose:
- To investigate the underlying pathogenesis of CIDP, focusing on axonal dysfunction and immune system involvement.
- To identify genetic factors, specifically single nucleotide polymorphism (SNP) haplotypes in TAG-1, associated with Intravenous immunoglobulin (IVIg) responsiveness in CIDP.
- To analyze gene expression profiles in biopsied nerves to understand differences between IVIg responders and non-responders.
Summary:
- Clinicopathological studies highlight axonal dysfunction as a key factor in IVIg non-responders.
- SNP analysis implicates TAG-1 in regulating potassium channels and influencing IVIg responsiveness.
- Gene expression data suggest CIDP pathogenesis involves both humoral and cellular immunity, with distinct therapeutic needs for responders and non-responders.
Impact:
- Findings suggest that while all CIDP patients may benefit from immune-modulating therapies, the approach needs refinement.
- Non-responders may require novel therapeutic strategies beyond conventional treatments to address pathogenesis.
- IVIg responders might necessitate more intensive and prolonged immunosuppression.
